Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chinese Regulatory Changes Key To Life Sciences Investment Decisions – BioMedical Asia

This article was originally published in PharmAsia News

Executive Summary

SINGAPORE - Regulatory reforms during the next several years will help define the next generation of winners and losers in the China life sciences industry, and investors are anxiously parsing the landscape for any signals of how the changes might play out. But trying to predict what will come next out of a notoriously opaque regulatory process is an ongoing challenge for venture capitalists and bankers alike, as evidenced by a panel discussion on Chinese investment opportunities held March 18 during the annual BioMedical Asia conference in Singapore
Advertisement

Related Content

Wuxi And Qiagen Form Biomarker Partnership In Shanghai
Wuxi And Qiagen Form Biomarker Partnership In Shanghai
Medical Device Sector Expected To Gain The Most From China’s Healthcare Reform
Despite Global Financial Crisis, China Pharma Market Expected To Grow At 20% Over Next Several Years
Chinese Regulatory Changes Key To Life Sciences Investment Decisions – BioMedical Asia
More Investment In China’s Health Care System Unveiled During NPC;  Is It Time To Ask Who Will Benefit First And Most?
More Investment In China’s Health Care System Unveiled During NPC;  Is It Time To Ask Who Will Benefit First And Most?
China Debates Changes In Government Price Ceilings On Drugs As Part Of Health System Reforms
Funding Crisis Hits China Life Sciences Industry, But China Is Faring Better Than The West
Yangtze Delta Expected To Be Largest CRO Cluster By 2015
Advertisement
UsernamePublicRestriction

Register

SC071070

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel